-transparent.png){kind=logo}
The metabolic fate of the anti-Parkinsonian drug budipine was studied in rats after oral administration. The presence of an aromatic hydroxylation product, metabolite M1, and its O-sulphate conjugate was confirmed. Three new minor metabolites, budipine N-oxide, metabolite M1 N-oxide and a secondary metabolite derived from M1 via hydroxylation of a methyl of the tert-butyl group, were isolated and identified in rat urine. The presence of a metabolite M1-glucuronic acid conjugate, was also established through different enzymatic treatments of the rat urine.
Related Publications
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
September 1994,
Neuroscience letters,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
May 1989,
Arzneimittel-Forschung,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
January 1986,
Psychopharmacology,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
April 2001,
Journal of drug targeting,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
March 1989,
Arzneimittel-Forschung,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
September 2009,
Neuroscience,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
April 1958,
Wiener klinische Wochenschrift,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
June 2016,
Journal of agricultural and food chemistry,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
March 1972,
Xenobiotica; the fate of foreign compounds in biological systems,
O Caputo, and
G Grosa, and
M Ceruti, and
F Rocco, and
G Biglino
January 2000,
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
